Reneo Pharmaceuticals Stock Price To Sales
RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Reneo Pharmaceuticals fundamentals help investors to digest information that contributes to Reneo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reneo Stock. The fundamental analysis module provides a way to measure Reneo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reneo Pharmaceuticals stock.
Reneo |
Reneo Pharmaceuticals Company Price To Sales Analysis
Reneo Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Reneo Pharmaceuticals has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Reneo Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reneo Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics of similar companies.Reneo Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Reneo Fundamentals
Return On Equity | -0.54 | |||
Return On Asset | -0.34 | |||
Current Valuation | (15.01 M) | |||
Shares Outstanding | 3.34 M | |||
Shares Owned By Insiders | 5.19 % | |||
Shares Owned By Institutions | 87.75 % | |||
Number Of Shares Shorted | 3.4 M | |||
Price To Book | 0.79 X | |||
EBITDA | (82.23 M) | |||
Net Income | (77.39 M) | |||
Cash And Equivalents | 126.85 M | |||
Cash Per Share | 5.18 X | |||
Total Debt | 973 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 15.84 X | |||
Book Value Per Share | 2.30 X | |||
Cash Flow From Operations | (63.68 M) | |||
Short Ratio | 27.39 X | |||
Earnings Per Share | (16.80) X | |||
Target Price | 2.25 | |||
Beta | 0.22 | |||
Market Capitalization | 6.08 M | |||
Total Asset | 107.44 M | |||
Retained Earnings | (218.47 M) | |||
Working Capital | 88.44 M | |||
Net Asset | 107.44 M |
About Reneo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reneo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |